Incidence in the management of bone tumors with Polymethylmethacrylate: Multicenter study, Caracas 2013-2023

Abstract

Primary bone cancer is a rare condition, representing less than 1% of all cancers diagnosed. It manifests as primary bone tumors, which originate in bone tissue and can be either benign or malignant. Surgical treatment is essential, with curettage being the most commonly used method, often combined with adjunctive surgical therapy. One of the techniques described is the use of polymethylmethacrylate (PMMA) to prevent recurrences. This study was observational, descriptive, retrospective, and cross-sectional. The majority of patients were between 26 and 50 years old (55%), with a predominance of females (60%). The year with the highest incidence of cases was 2016 (27.5%). The most common lesion was Giant Cell Tumor (67.5%). The most frequent intervention was intralesional resection with PMMA reconstruction in 72.5% of cases. Pain was the predominant clinical symptom (100%), and the most common location was the femur (45%). Results from the MSTS scale showed that 90% of cases involved the lower limbs, and the mean functionality score was "good" in 86.11% of cases. In conclusion, the study achieved its goal of analyzing the frequency of bone tumor management with PMMA and the recurrence rate in patients treated at the Centro Médico Docente La Trinidad and Hospital Padre Machado between 2013 and 2023. The findings suggest that PMMA is a viable option for preserving bone function, due to its low recurrence rate.